$NPCE

NeuroPace Inc (NPCE): Submission of Matters to a Vote of Security Holders

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NeuroPace Inc false 0001528287 0001528287 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report

Original reporting
Published Jun 8, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NPCE
Neutral
medium confidence
Mentioned
$NPCE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NPCENeutralLow
01

Why it matters

Confirms election of Class II directors (Lisa Andrade, Scott Huennekens) and ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending Dec. 31, 2026.

02

Market read

This is a governance/administrative disclosure with limited direct trading implications absent additional catalysts.

03

What to watch

Traders may still watch for follow-on proxy/board actions or subsequent filings (e.g., post-meeting board composition) that could affect governance expectations.

Relevance 6/10Novelty 4/10Timing: after-hours / filed June 8, 2026

Background

The company’s 8-K reports final voting results from its 2026 Annual Meeting held virtually on June 5, 2026.

Company-level read

Ticker impact

$NPCENeutralMedium confidence
Context

NeuroPace filed an 8-K detailing the June 5, 2026 annual meeting vote results, including director elections and auditor ratification.

Expected impact

Likely minimal near-term impact; any move would be more sentiment/positioning than fundamentals.

Evidence & confidence

The filing reports routine shareholder-meeting results (director election and PwC ratification) without new financial guidance, clinical updates, or transactions.

Market effects

No direct read-across to the neurostimulation/medtech sector beyond routine corporate governance.

None indicated.

None indicated.

Counterpoint

Even routine votes can matter if there were contested governance issues, but this filing shows standard outcomes without controversy details.

Key entities

  • NeuroPace, Inc.

    Reported annual meeting vote results on director elections and auditor ratification via SEC Form 8-K.

  • PricewaterhouseCoopers LLP

    Ratified as NeuroPace’s independent registered public accounting firm for FY2026.

Related articles

$NPCEMed

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which a